South Korea Orphan Drugs Market Report by Drug Type (Biological, Non-Biological), Disease Type (Oncology, Hematology, Neurology, Cardiovascular, and Others), Phase (Phase I, Phase II, Phase III, Phase IV), Top Selling Drugs (Revlimid, Rituxan, Copaxone, Opdivo, Keytruda, Imbruvica, Avonex, Sensipar, Soliris, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Stores, and Others), and Region 2026-2034

July 2026 | 117 pages | ID: S4F9165242DCEN
IMARC Group

Abstracts

South Korea orphan drugs market size reached USD 5.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 11.7 Billion by 2034, exhibiting a growth rate (CAGR) of 9.56 % during 2026-2034. The launch of favorable policies by government bodies to inhibit the spread of contagious diseases is primarily driving the regional market.

Orphan drugs are pharmaceutical products designed for the diagnosis, prevention, and treatment of rare medical disorders. These drugs are specifically developed to address a particular public health need and typically have a limited market due to their production for a small patient population. They prove effective against a range of conditions, including oncological, metabolic, hematologic, immunologic, infectious, and neurological diseases. Conditions such as lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma, and renal cell carcinoma fall under the category of orphan drug applications. These medical conditions are often characterized by being life-threatening, chronic, progressive, degenerative, and disabling, necessitating tailored treatment options that are effective in addressing their unique symptoms.

SOUTH KOREA ORPHAN DRUGS MARKET TRENDS:

The South Korea orphan drugs market has emerged as a critical component within the nation's healthcare landscape, addressing the specific medical needs of individuals affected by rare disorders. The regional market offers effective solutions against a spectrum of medical conditions, encompassing oncological, metabolic, hematologic, immunologic, infectious, and neurological diseases. Additionally, conditions, such as lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma, and renal cell carcinoma fall under the ambit of orphan drug applications. Moreover, these medical disorders often present life-threatening, chronic, progressive, degenerative, and disabling characteristics, necessitating specialized treatment alternatives that can effectively address their distinctive symptoms. Besides this, as South Korea continues to advance in healthcare innovation, the orphan drugs market becomes integral in providing targeted and efficacious solutions for patients facing rare medical challenges. The focus on precision medicine and tailored treatments aligns with the nation's commitment to delivering advanced healthcare solutions. The South Korea stands as a pivotal player in the provision of specialized therapies that enhance the quality of life for individuals grappling with rare disorders, which is expected to fuel the regional market in the coming years.

SOUTH KOREA ORPHAN DRUGS MARKET SEGMENTATION:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2026-2034. Our report has categorized the market based on drug type, disease type, phase, top selling drugs, and distribution channel.

Drug Type Insights:

• Biological
• Non-Biological

The report has provided a detailed breakup and analysis of the market based on the drug type. This includes biological and non-biological.

Disease Type Insights:

• Oncology
• Hematology
• Neurology
• Cardiovascular
• Others

A detailed breakup and analysis of the market based on the disease type have also been provided in the report. This includes oncology, hematology, neurology, cardiovascular, and others.

Phase Insights:

• Phase I
• Phase II
• Phase III
• Phase IV

The report has provided a detailed breakup and analysis of the market based on the phase. This includes phase I, phase II, phase III, and phase IV.

Top Selling Drugs Insights:

• Revlimid
• Rituxan
• Copaxone
• Opdivo
• Keytruda
• Imbruvica
• Avonex
• Sensipar
• Soliris
• Others

A detailed breakup and analysis of the market based on the top selling drugs have also been provided in the report. This includes revlimid, rituxan, copaxone, opdivo, keytruda, imbruvica, avonex, sensipar, soliris, and others.

Distribution Channel Insights:

• Hospital Pharmacies
• Retail Pharmacies
• Online Stores
• Others

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, online stores, and others.

Regional Insights:

• Seoul Capital Area
• Yeongam (Southeastern Region)
• Honam (Southwestern Region)
• Hoseo (Central Region)
• Others

The report has also provided a comprehensive analysis of all the major regional markets, which include Seoul Capital Area, Yeongam (Southeastern Region), Honam (Southwestern Region), Hoseo (Central Region), and Others.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

KEY QUESTIONS ANSWERED IN THIS REPORT
How has the South Korea orphan drugs market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the South Korea orphan drugs market?
What is the breakup of the South Korea orphan drugs market on the basis of drug type?
What is the breakup of the South Korea orphan drugs market on the basis of disease type?
What is the breakup of the South Korea orphan drugs market on the basis of phase?
What is the breakup of the South Korea orphan drugs market on the basis of top selling drugs?
What is the breakup of the South Korea orphan drugs market on the basis of distribution channel?
What are the various stages in the value chain of the South Korea orphan drugs market?
What are the key driving factors and challenges in the South Korea orphan drugs?
What is the structure of the South Korea orphan drugs market and who are the key players?
What is the degree of competition in the South Korea orphan drugs market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
  2.3.1 Primary Sources
  2.3.2 Secondary Sources
2.4 Market Estimation
  2.4.1 Bottom-Up Approach
  2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 SOUTH KOREA ORPHAN DRUGS MARKET - INTRODUCTION

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 SOUTH KOREA ORPHAN DRUGS MARKET LANDSCAPE

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 SOUTH KOREA ORPHAN DRUGS MARKET - BREAKUP BY DRUG TYPE

6.1 Biological
  6.1.1 Overview
  6.1.2 Historical and Current Market Trends (2020-2025)
  6.1.3 Market Forecast (2026-2034)
6.2 Non-Biological
  6.2.1 Overview
  6.2.2 Historical and Current Market Trends (2020-2025)
  6.2.3 Market Forecast (2026-2034)

7 SOUTH KOREA ORPHAN DRUGS MARKET - BREAKUP BY DISEASE TYPE

7.1 Oncology
  7.1.1 Overview
  7.1.2 Historical and Current Market Trends (2020-2025)
  7.1.3 Market Forecast (2026-2034)
7.2 Hematology
  7.2.1 Overview
  7.2.2 Historical and Current Market Trends (2020-2025)
  7.2.3 Market Forecast (2026-2034)
7.3 Neurology
  7.3.1 Overview
  7.3.2 Historical and Current Market Trends (2020-2025)
  7.3.3 Market Forecast (2026-2034)
7.4 Cardiovascular
  7.4.1 Overview
  7.4.2 Historical and Current Market Trends (2020-2025)
  7.4.3 Market Forecast (2026-2034)
7.5 Others
  7.5.1 Historical and Current Market Trends (2020-2025)
  7.5.2 Market Forecast (2026-2034)

8 SOUTH KOREA ORPHAN DRUGS MARKET - BREAKUP BY PHASE

8.1 Phase I
  8.1.1 Overview
  8.1.2 Historical and Current Market Trends (2020-2025)
  8.1.3 Market Forecast (2026-2034)
8.2 Phase II
  8.2.1 Overview
  8.2.2 Historical and Current Market Trends (2020-2025)
  8.2.3 Market Forecast (2026-2034)
8.3 Phase III
  8.3.1 Overview
  8.3.2 Historical and Current Market Trends (2020-2025)
  8.3.3 Market Forecast (2026-2034)
8.4 Phase IV
  8.4.1 Overview
  8.4.2 Historical and Current Market Trends (2020-2025)
  8.4.3 Market Forecast (2026-2034)

9 SOUTH KOREA ORPHAN DRUGS MARKET - BREAKUP BY TOP SELLING DRUGS

9.1 Revlimid
  9.1.1 Overview
  9.1.2 Historical and Current Market Trends (2020-2025)
  9.1.3 Market Forecast (2026-2034)
9.2 Rituxan
  9.2.1 Overview
  9.2.2 Historical and Current Market Trends (2020-2025)
  9.2.3 Market Forecast (2026-2034)
9.3 Copaxone
  9.3.1 Overview
  9.3.2 Historical and Current Market Trends (2020-2025)
  9.3.3 Market Forecast (2026-2034)
9.4 Opdivo
  9.4.1 Overview
  9.4.2 Historical and Current Market Trends (2020-2025)
  9.4.3 Market Forecast (2026-2034)
9.5 Keytruda
  9.5.1 Overview
  9.5.2 Historical and Current Market Trends (2020-2025)
  9.5.3 Market Forecast (2026-2034)
9.6 Imbruvica
  9.6.1 Overview
  9.6.2 Historical and Current Market Trends (2020-2025)
  9.6.3 Market Forecast (2026-2034)
9.7 Avonex
  9.7.1 Overview
  9.7.2 Historical and Current Market Trends (2020-2025)
  9.7.3 Market Forecast (2026-2034)
9.8 Sensipar
  9.8.1 Overview
  9.8.2 Historical and Current Market Trends (2020-2025)
  9.8.3 Market Forecast (2026-2034)
9.9 Soliris
  9.9.1 Overview
  9.9.2 Historical and Current Market Trends (2020-2025)
  9.9.3 Market Forecast (2026-2034)
9.10 Others
  9.10.1 Historical and Current Market Trends (2020-2025)
  9.10.2 Market Forecast (2026-2034)

10 SOUTH KOREA ORPHAN DRUGS MARKET - BREAKUP BY DISTRIBUTION CHANNEL

10.1 Hospital Pharmacies
  10.1.1 Overview
  10.1.2 Historical and Current Market Trends (2020-2025)
  10.1.3 Market Forecast (2026-2034)
10.2 Retail Pharmacies
  10.2.1 Overview
  10.2.2 Historical and Current Market Trends (2020-2025)
  10.2.3 Market Forecast (2026-2034)
10.3 Online Stores
  10.3.1 Overview
  10.3.2 Historical and Current Market Trends (2020-2025)
  10.3.3 Market Forecast (2026-2034)
10.4 Others
  10.4.1 Historical and Current Market Trends (2020-2025)
  10.4.2 Market Forecast (2026-2034)

11 SOUTH KOREA ORPHAN DRUGS MARKET – BREAKUP BY REGION

11.1 Seoul Capital Area
  11.1.1 Overview
  11.1.2 Historical and Current Market Trends (2020-2025)
  11.1.3 Market Breakup by Drug Type
  11.1.4 Market Breakup by Disease Type
  11.1.5 Market Breakup by Phase
  11.1.6 Market Breakup by Top Selling Drugs
  11.1.7 Market Breakup by Distribution Channel
  11.1.8 Key Players
  11.1.9 Market Forecast (2026-2034)
11.2 Yeongam (Southeastern Region)
  11.2.1 Overview
  11.2.2 Historical and Current Market Trends (2020-2025)
  11.2.3 Market Breakup by Drug Type
  11.2.4 Market Breakup by Disease Type
  11.2.5 Market Breakup by Phase
  11.2.6 Market Breakup by Top Selling Drugs
  11.2.7 Market Breakup by Distribution Channel
  11.2.8 Key Players
  11.2.9 Market Forecast (2026-2034)
11.3 Honam (Southwestern Region)
  11.3.1 Overview
  11.3.2 Historical and Current Market Trends (2020-2025)
  11.3.3 Market Breakup by Drug Type
  11.3.4 Market Breakup by Disease Type
  11.3.5 Market Breakup by Phase
  11.3.6 Market Breakup by Top Selling Drugs
  11.3.7 Market Breakup by Distribution Channel
  11.3.8 Key Players
  11.3.9 Market Forecast (2026-2034)
11.4 Hoseo (Central Region)
  11.4.1 Overview
  11.4.2 Historical and Current Market Trends (2020-2025)
  11.4.3 Market Breakup by Drug Type
  11.4.4 Market Breakup by Disease Type
  11.4.5 Market Breakup by Phase
  11.4.6 Market Breakup by Top Selling Drugs
  11.4.7 Market Breakup by Distribution Channel
  11.4.8 Key Players
  11.4.9 Market Forecast (2026-2034)
11.5 Others
  11.5.1 Historical and Current Market Trends (2020-2025)
  11.5.2 Market Forecast (2026-2034)

12 SOUTH KOREA ORPHAN DRUGS MARKET – COMPETITIVE LANDSCAPE

12.1 Overview
12.2 Market Structure
12.3 Market Player Positioning
12.4 Top Winning Strategies
12.5 Competitive Dashboard
12.6 Company Evaluation Quadrant

13 PROFILES OF KEY PLAYERS

13.1 Company A
  13.1.1 Business Overview
  13.1.2 Product Portfolio
  13.1.3 Business Strategies
  13.1.4 SWOT Analysis
  13.1.5 Major News and Events
13.2 Company B
  13.2.1 Business Overview
  13.2.2 Product Portfolio
  13.2.3 Business Strategies
  13.2.4 SWOT Analysis
  13.2.5 Major News and Events
13.3 Company C
  13.3.1 Business Overview
  13.3.2 Product Portfolio
  13.3.3 Business Strategies
  13.3.4 SWOT Analysis
  13.3.5 Major News and Events
13.4 Company D
  13.4.1 Business Overview
  13.4.2 Product Portfolio
  13.4.3 Business Strategies
  13.4.4 SWOT Analysis
  13.4.5 Major News and Events
13.5 Company E
  13.5.1 Business Overview
  13.5.2 Product Portfolio
  13.5.3 Business Strategies
  13.5.4 SWOT Analysis
  13.5.5 Major News and Events

14 SOUTH KOREA ORPHAN DRUGS MARKET - INDUSTRY ANALYSIS

14.1 Drivers, Restraints, and Opportunities
  14.1.1 Overview
  14.1.2 Drivers
  14.1.3 Restraints
  14.1.4 Opportunities
14.2 Porters Five Forces Analysis
  14.2.1 Overview
  14.2.2 Bargaining Power of Buyers
  14.2.3 Bargaining Power of Suppliers
  14.2.4 Degree of Competition
  14.2.5 Threat of New Entrants
  14.2.6 Threat of Substitutes
14.3 Value Chain Analysis

15 APPENDIX